secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001787306-22-000050
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports Q2 net loss $67.4M; FDA approved ZORYVE for plaque psoriasis
----------------------------------------------------------------------------

- FDA approved ZORYVE (roflumilast cream) for plaque psoriasis in patients 12+; launch expected in coming weeks.
- Positive Phase 3 topline for roflumilast foam in seborrheic dermatitis; NDA submission planned Q1 2023.
- Completed enrollment in INTEGUMENT-1 atopic dermatitis trial; topline data by end of 2022.
- Cash $283.4M at June 30; pro forma ~$570M after $162M equity net + $125M debt draw.
- Q2 net loss $67.4M ($1.31/sh) vs $42.0M ($0.84/sh) in Q2 2021, driven by R&D and G&A increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000050/0001787306-22-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000050/arqt-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer